Sierra Oncology, Inc. (NASDAQ: SRRA) is focussed on creating novel targeted therapies that address large unmet needs in rare forms of cancer. The Company’s lead product candidate is momelotinib, a selective and orally bioavailable JAK1, JAK2 and ACVR1/ALK2 inhibitor being developed for the treatment of...
Infinity Pharmaceuticals (NASDAQ: INFI) novel approach is based on Targeting Immune Suppressive Macrophages by selectively inhibiting PI3K-Gamma. The Company’s lead candidate eganelisib, is a first-in-class, oral, once-daily selective inhibitor of phosphoinositide-3-kinase gamma (PI3K-gamma), that has the potential to transform the immuno-oncology space. IPI-549 has demonstrated...
Sesen Bio, Inc. (NASDAQ: SESN) is focused on creating targeted fusion protein therapeutics (TFPTs) for treatment of cancers. The Company is looking at a major catalyst in 2021, the approval of Vicineum, a potential best-in-class therapeutic for the treatment of non-muscle invasive bladder cancer (NMIBC)...
